Fedratinib and Panobinostat Lactate
Determining the interaction of Fedratinib and Panobinostat Lactate and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.MONITOR CLOSELY: Coadministration of panobinostat and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. Treatment with panobinostat has been associated with severe thrombocytopenia and hemorrhage (including gastrointestinal and pulmonary hemorrhage) with fatal outcomes. The risk may be increased in patients with coagulation disorders or those on chronic anticoagulation therapy. In a phase III clinical trial in patients with relapsed multiple myeloma, treatment-emergent grade 3 to 4 (CTCAE) thrombocytopenia and hemorrhage was reported in 67% and 4.2% of panobinostat-treated patients, respectively. In the same phase III clinical trial, there were 5 patients treated with panobinostat who died due to a hemorrhagic event, compared to 1 in the control arm. The patients with fatal bleeding events reported in the clinical trial had at least grade 3 (CTCAE) thrombocytopenia at the time of the event. MANAGEMENT: Concomitant use of other medications that interfere with platelet function or coagulation should be considered cautiously in patients treated with panobinostat. Close clinical and laboratory observation for bleeding complications is recommended during therapy. A complete blood cell count should be performed prior to and at least weekly during treatment according to treatment protocols, including monitoring for thrombocytopenia. Dose modifications may be required based on individual patient tolerability. Patients should be advised to promptly report any signs of bleeding to their doctor, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools. Since panobinostat is indicated in combination with bortezomib and dexamethasone, the manufacturer labeling for these products should also be consulted for additional information. References Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0 Cerner Multum, Inc. "Australian Product Information." O 0 "Product Information. Farydak (panobinostat)." Novartis Pharmaceuticals, East Hanover, NJ.
Professional:MONITOR CLOSELY: Coadministration of panobinostat and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. Treatment with panobinostat has been associated with severe thrombocytopenia and hemorrhage (including gastrointestinal and pulmonary hemorrhage) with fatal outcomes. The risk may be increased in patients with coagulation disorders or those on chronic anticoagulation therapy. In a phase III clinical trial in patients with relapsed multiple myeloma, treatment-emergent grade 3 to 4 (CTCAE) thrombocytopenia and hemorrhage was reported in 67% and 4.2% of panobinostat-treated patients, respectively. In the same phase III clinical trial, there were 5 patients treated with panobinostat who died due to a hemorrhagic event, compared to 1 in the control arm. The patients with fatal bleeding events reported in the clinical trial had at least grade 3 (CTCAE) thrombocytopenia at the time of the event.
MANAGEMENT: Concomitant use of other medications that interfere with platelet function or coagulation should be considered cautiously in patients treated with panobinostat. Close clinical and laboratory observation for bleeding complications is recommended during therapy. A complete blood cell count should be performed prior to and at least weekly during treatment according to treatment protocols, including monitoring for thrombocytopenia. Dose modifications may be required based on individual patient tolerability. Patients should be advised to promptly report any signs of bleeding to their doctor, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools. Since panobinostat is indicated in combination with bortezomib and dexamethasone, the manufacturer labeling for these products should also be consulted for additional information.
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- Cerner Multum, Inc. "Australian Product Information." O 0
- "Product Information. Farydak (panobinostat)." Novartis Pharmaceuticals, East Hanover, NJ.
Generic Name: panobinostat
Brand name: Farydak
Synonyms: Panobinostat
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Fedratinib-Panocaps
- Fedratinib-PanOxyl
- Fedratinib-Panoxyl Soap
- Fedratinib-PanOxyl Wash
- Fedratinib-PanOxyl-4 Creamy Wash
- Fedratinib-PanOxyl-8 Creamy Wash
- Panobinostat Lactate-Fedratinib Hydrochloride
- Panobinostat Lactate-Feiba
- Panobinostat Lactate-Feiba NF
- Panobinostat Lactate-Feiba VH Immuno
- Panobinostat Lactate-Feiba-VH
- Panobinostat Lactate-Felbamate